Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHOP Commits $50 Million To Gene Therapy Spin-Out Spark Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

Non-profit hospital spins out its first start-up, which will house one program to address a heritable form of blindness, another to treat hemophilia B.


Related Content

Cellular And Gene Therapy Trials Should Target Children First, FDA Advisors Say
Third Rock Takes On Parkinson's, Gene Therapy's Next Frontier
Start-Up Quarterly Statistics, Q4 2013
Sanford-Burnham Hopes $275 Million Gift Will Translate To Returns
Voyager Lifts Off With $45M From Third Rock Ventures
Financings Of The Fortnight: Do Larger Series A Rounds Mean Less Successful Exits?
With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts